A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
The purpose of this study is to further quantify the risk of cerebrovascular events (CVEs) following sipuleucel-T (PROVENGEŽ) therapy, and to follow all subjects for survival.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : sipuleucel-T
Ages Eligible For Study:
- subjects must be at least 18 years of age - subjects with advanced prostate cancer who will receive sipuleucel-T or who underwent their first leukapheresis for manufacture of sipuleucel-T ? 6 months prior to enrollment - subjects must understand and sign an informed consent form